Combining the anti-EGFR agent gefitinib with chemotherapy in non-small-cell lung cancer: how do we go from INTACT to impact?

J Clin Oncol. 2004 Mar 1;22(5):759-61. doi: 10.1200/JCO.2004.12.903.
No abstract available

Publication types

  • Comparative Study
  • Editorial
  • Comment

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage*
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / mortality
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Clinical Trials, Phase III as Topic
  • ErbB Receptors / antagonists & inhibitors*
  • Female
  • Gefitinib
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / mortality
  • Lung Neoplasms / pathology
  • Male
  • Neoplasm Staging
  • Prognosis
  • Quinazolines / administration & dosage*
  • Randomized Controlled Trials as Topic
  • Risk Assessment
  • Sensitivity and Specificity
  • Survival Analysis
  • Treatment Outcome

Substances

  • Quinazolines
  • ErbB Receptors
  • Gefitinib